Novartis Investigative Site

Phillip, Australian Capital Territory 2606

0 studies enrolling now · 5 studies all time

What they study most

Chronic Plaque Type Psoriasis, Cutaneous Squamous Cell Carcinoma in Situ (CSCCis), Hidradenitis Suppurativa

Studies at this site

• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). — Completed
• Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) — Stopped early
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis — Completed